Impacts of Cytogenetic Abnormalities and Prior Alemtuzumab on Outcomes of Patients (pts) with High-Risk Chronic Lymphocytic Leukemia (CLL) Given Nonmyeloablative Allogeneic Hematopoietic Cell Transplantation (HCT)

被引：0
|
作者：
Sorror, Mohamed L. [1 ]
Storer, Barry [1 ]
Sandmaier, Brenda M. [1 ]
Braunert, Leanthe [2 ]
Laport, Ginna G. [3 ]
Chauncey, Thomas [1 ,4 ]
Bredeson, Christopher [5 ]
Maziarz, Richard T. [6 ]
Pulsipher, Michael A. [7 ]
Agura, Edward [8 ]
Mans, Michael T. [9 ]
Vindelov, Lars [10 ]
Sahebi, Firoozeh [11 ]
McSweeney, Peter [12 ]
Bruno, Benedetto [13 ]
Langston, Amelia [14 ]
Storb, Rainer F. [1 ]
Maloney, David G. [1 ]
机构：
[1] Univ Washington, Fred Hutchinson Canc Res Ctr, Seattle, WA 98195 USA
[2] Univ Leipzig, Leipzig, Germany
[3] Stanford Univ, Stanford, CA 94305 USA
[4] VA Puget Sound Hlth Care Syst, Seattle, WA USA
[5] Med Coll Wisconsin, Milwaukee, WI 53226 USA
[6] Oregon Hlth & Sci Univ, Portland, OR 97201 USA
[7] Univ Utah, Salt Lake City, UT USA
[8] Baylor Univ, Dallas, TX USA
[9] Rocky Mt Canc Ctr, Denver, CO USA
[10] Rigshosp, DK-2100 Copenhagen, Denmark
[11] City Hope Natl Med Ctr, Duarte, CA 91010 USA
[12] Univ Colorado, Boulder, CO 80309 USA
[13] Univ Turin, Turin, Italy
[14] Emory Univ, Winship Canc Inst, Atlanta, GA 30322 USA
来源：
BLOOD | 2010年 / 116卷 / 21期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：978 / 978
页数：1
相关论文
共 50 条
  • [1] Long-term follow up of patients (pts) with high-risk chronic lymphocytic leukemia (CLL) given nonmyeloablative allogeneic hematopoietic cell transplantation (HCT)
    Sorror, Mohamed L.
    Storer, Barry
    Sandmaier, Brenda M.
    Maris, Michael B.
    Shizuru, Judith
    Leis, Jose
    Agura, Edward
    Chauncey, Thomas
    Pulsipher, Michael
    McSweeney, Peter
    Wade, James
    Bruno, Benedetto
    Langston, Amelia
    Radich, Jerry
    Niederwieser, Dietger
    Blume, Karl
    Storb, Rainer
    Maloney, David G.
    BLOOD, 2007, 110 (11) : 496A - 496A
  • [2] Longer follow up of patients (PTS) with advanced chronic lymphocytic leukemia (CLL) treated with nonmyeloablative conditioning and allogeneic hematopoietic cell transplantation (HCT)
    Sorror, M. L.
    Storer, B.
    Sandmaier, B. M.
    Maris, M. B.
    Shizuru, J.
    Niederwieser, D.
    Agura, E.
    Chauncey, T.
    Maziarz, R.
    Pulsipher, M.
    McSweeney, P.
    Wade, J.
    Bruno, B.
    Langston, A.
    Blume, K.
    Storb, R.
    Maloney, D. G.
    BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2007, 13 (02) : 133 - 134
  • [3] ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION (HCT) IN CHEMOTHERAPY REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA (CLL)
    Aljitawi, O. S.
    Krishnana, A.
    Nademance, A.
    Palmer, J.
    Alvarnas, J.
    Cai, J. -L.
    Kirschbaum, M.
    Kogut, N.
    Nakamura, R.
    Popplewell, L.
    Sarkodee-Adoo, C.
    Schriber, J.
    Zain, J.
    Parker, F.
    Forman, P.
    BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2008, 14 (02) : 109 - 109
  • [4] EARLY RESULTS OF A PHASE II STUDY ADDING PERI-TRANSPLANT RITUXIMAB TO NONMYELOABLATIVE CONDITIONING AND ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION (HCT) FOR PATIENTS (PTS) WITH HIGH-RISK FLUDARABINE-REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA (CLL)
    Sorror, M. L.
    Storer, B.
    Sandmaier, B. M.
    Chauncey, T.
    Bruno, B.
    Andersen, N. N. S.
    Hogan, W. J.
    Storb, R.
    Maloney, D.
    BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2012, 18 (02) : S289 - S290
  • [5] Allogeneic hematopoietic cell transplantation after prior targeted therapy for high-risk chronic lymphocytic leukemia
    Kim, Haesook T.
    Shaughnessy, Conner J.
    Rai, Sharmila C.
    Reynolds, Carol
    Ho, Vincent T.
    Cutler, Corey
    Koreth, John
    Gooptu, Mahasweta
    Romee, Rizwan
    Nikiforow, Sarah
    Armand, Philippe
    Alyea, Edwin P.
    Antin, Joseph H.
    Wu, Catherine J.
    Soiffer, Robert J.
    Ritz, Jerome
    Brown, Jennifer R.
    BLOOD ADVANCES, 2020, 4 (17) : 4113 - 4123
  • [6] Nonmyeloablative (NM) conditioning and allogeneic hematopoietic cell transplantation (HCT) with HLA-matched unrelated donor (URD) for patients (Pts) with chemotherapy-refractory chronic lymphocytic leukemia (CLL).
    Sorror, ML
    Maris, M
    Storer, B
    Sandmaier, BM
    Maloney, DG
    Stuart, MJ
    Pulsipher, M
    McSweeney, PA
    Leis, JF
    Wade, JC
    Blume, KG
    Storb, RF
    BLOOD, 2003, 102 (11) : 482A - 482A
  • [7] Alemtuzumab Use and Survival After Reduced Intensity Allogeneic Stem Cell Transplantation in High-Risk Chronic Lymphocytic Leukemia (CLL)
    Ding, Wei
    Shanafelt, Tait D.
    Rabe, Kari
    Call, Timothy G.
    Zent, Clive S.
    Kay, Neil
    Inwards, David James
    Bowen, Deborah
    Litzow, Mark R.
    Slager, Susan L.
    Schwager, Susan
    Hogan, William J.
    BLOOD, 2011, 118 (21) : 1776 - 1776
  • [8] Nonmyeloablative hematopoietic cell transplantation (HCT) for treatment of patients (pts) with fludarabine-refractory chronic lymphocytic leukemia (CLL) results in prolonged median survival.
    Sorror, M.
    Sandmaier, B.
    Maris, M.
    Storer, B.
    Radich, J.
    Agura, E.
    Niederwieser, D.
    Blume, K.
    Storb, R.
    Maloney, D.
    JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (18) : 342S - 342S
  • [9] Sequential Autologous Followed by Nonmyeloablative Allogeneic Hematopoietic Cell Transplantation (HCT) From HLA-Matched Related or Unrelated Donors Improves Outcomes of Patients (pts) with Bulky Lymphoma or Chronic Lymphocytic Leukemia (CLL)
    Sorror, Mohamed L.
    Storer, Bany
    Sandmaier, Brenda M.
    Chauncey, Thomas
    Maris, Michael T.
    Storb, Rainer F.
    Maloney, David G.
    BLOOD, 2010, 116 (21) : 979 - 979
  • [10] Allogeneic hematopoietic stem cell transplantation with nonmyeloablative conditioning for patients with chronic lymphocytic leukemia.
    Flowers, CR
    Maloney, DG
    Sandmaier, BM
    Shizuru, JA
    McSweeney, PA
    Chauncey, TR
    Niederwieser, D
    Sahebi, F
    Agura, E
    Blume, K
    Forman, S
    Storb, R
    BLOOD, 2001, 98 (11) : 418A - 418A
12345